Labigat

Ranolazine, the active ingredient in Labigat, is an antianginal presented as an oral tablet for oral use. It treats chronic stable angina and myocardial ischemia in adults.

GNH USA supplies Labigat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ranolazine is used to manage conditions related to myocardial oxygen demand and supply.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Myocardial ischemia: enhances myocardial relaxation and decreases oxygen consumption. - Angina pectoris: improves quality of life by alleviating chest pain during physical activity.

Ranolazine may cause a range of adverse reactions.

Common Side Effects: - Dizziness - Headache - Nausea - Constipation - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmias - Severe hypotension - Elevated liver enzymes - Allergic reactions such as rash or angioedema

Before prescribing Ranolazine, consider the following safety measures.

- Renal impairment: assess renal function and adjust dose if needed. - Hepatic impairment: monitor liver function tests regularly. - Concomitant strong CYP3A4 inhibitors: avoid due to increased plasma concentrations. - Pregnancy: risk unknown; use only if potential benefit justifies the potential risk. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Ranolazine can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase Ranolazine levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Other antianginal agents: may increase risk of hypotension. - Digoxin: Ranolazine can raise digoxin concentrations. - Anticoagulants/antiplatelet drugs: monitor for enhanced bleeding tendency.